Clinical Trial Search

Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants

Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants

Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…

Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 DLTs

Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects

Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants

Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities

Primary: Maximum Tolerated Dose — 1 mCi/kg

Primary: Continuous Complete Remission at 3 Years — 74 percentage of participants

Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants

Primary: Overall Survival (Induction Phase) — 15.7; 23.7 months

Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants

Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…

Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants

Primary: Participants With a Complete Response — 34 Participants

Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants

Primary: Complete Response — 11 percentage of participants

Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients

Primary: Event-free Survival (EFS) at 3 Years — 90.1 percentage

Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg

Primary: Rate of Hospital Admission During Outpatient Induction Chemotherapy — 3; 14 Participants

Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants

Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)

Primary: Clinical Response (Complete and Partial) — 0; 4; 4; 5 Participants

Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants

Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants

Primary: Cellular Immune Response — 4 participants

Primary: Recommended Phase 2 Dose of LY573636-Sodium in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Essential Thrombocythemia (ET)

Primary: Clinical Response at the End of Temozolomide Induction — 10; 2; 4; 8 participants

Primary: Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients — 13; 14 Participants — p=<.05